Detection of Minimal Residual Disease: Methods and Relationship to Outcome in T-Lineage Acute Lymphoblastic Leukemia

References

• Wasserman R, Galili N, Ito Y, Silver J H, Reichard B A, Shane S, Womer R B, Lange B, Rovera G. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. Journal of Clinical Oncology 1992; 10: 1879–84
   PubMed Web of Science ®Google Scholar
• Brisco M J, Condon J, Hughes E, Neoh S H, Sykes P J, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196
   PubMed Web of Science ®Google Scholar
• Pullen D J, Crist W M, Falletta J M, . A Pediatric Oncology Group classification protocol for acute lymphoblastic leukemia (AlinC 13): immunologic phenotypes and correlation with treated results. Leukemia Research: Advances in Biology and Treatment, S Murphy, J Gilbert, et al. Elsevier in Hollan, Experta Medica, New York 1983; 22
   Google Scholar
• Van Dongen J JM, Wolvers-Tettero I LM. Analysis of immunoglobulin and T-cell receptor genes. Part 1: Basic and technical aspects. Clinical Chimica Acta 1991; 198: 1
   PubMed Web of Science ®Google Scholar
• Davis M M, Bjorkmann P J. T-Cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395
   PubMed Web of Science ®Google Scholar
• La Faille J J, Decloux A, Bonneville M, Takagaki Y, Tonegawa S. Junctional sequences of T-cell receptor γδ genes: implications of γδ T-cell lineages and for a novel intermediate of V-(D)-J joining. Cell 1989; 59: 859–863
   PubMed Web of Science ®Google Scholar
• Breit T M, Wolvers- Tettero I LM, Hahlen K, Van Wering F R, Van Dongen J JM. Extensive junctional diversity of γδ T-cell receptors expressed by T-cell acute lymphoblastic leukemias: implications for the detection of minimal residual disease. Leukemia 1991; 5: 1076–1081
   PubMed Web of Science ®Google Scholar
• Carrol A J, Crist W M, Link M P, Amylon M D, Pullen D J, Ragab A H, Buchanan G R, Wimmer R S, Vietti T J. The t(1;14) (p3.4; q1.1) translocation is non-random and restricted to T-cell acute lymphoblastic leukemia. A Pediatric Oncology Group Study. Blood 1990; 76: 1220–24
   PubMed Web of Science ®Google Scholar
• Brown L, Cheng J-T, Chen Q, Siciliano M J, Crist W, Buchanan G R, Baer R. Site-specific recombination of the TAL 1 gene is a common occurrence in human T-cell leukemia. EMBO Journal 1990; 9: 3343–51
   PubMed Web of Science ®Google Scholar
• Bernard O, Lecointe N, Jonveaux P, Soury M, Mauchauffe M, Berger R, Larson C J, Mathie-Mahul D. Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the TAL 1 gene. Oncogene 1991; 6: 1477–88
   PubMed Web of Science ®Google Scholar
• Apian P D, Lombardi P D, Reaman G H, Sather H R, Hammond G D, Krisch I R. Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood 1992; 79: 1327–1333
   PubMed Web of Science ®Google Scholar
• Jonsson O G, Kitchens R L, Baer R J, Buchanan G R, Smith R G. Rearrangements of the TAL-1 locus as clonal markers for T-cell acute lymphoblastic leukemia. Journal of Clinical Investigation 1991; 87: 2029–34
   PubMed Web of Science ®Google Scholar
• Breit T M, Beishuizen A, Ludwig W D, Mol E J, Adriaasen H J, Van Wering E R, Van Dongen J JM. Tal-1 deletions in T-cell acute lymphoblastic leukemia as PCR target for detection of minimal residual disease. Leukemia 1993; 7: 2004–11
   PubMed Web of Science ®Google Scholar
• Bash R O, Crist W, Shuster J J, Link M P, Amylon M, Pullen J, Carrol A, Buchanan G R, Smith G, Baer R. Clinical features and outcome of T-cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL 1 locus: a Pediatric Oncology Group Study. Blood 1993; 81: 2110–2117
   PubMed Web of Science ®Google Scholar
• Pui C H, Behm F G, Crist W M. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343–9
   PubMed Web of Science ®Google Scholar
• Van Dongen J JM, Wolvers-Tettero I LM. Analysis of immunoglobulin and T-Cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clinical Chimica Acta 1991; 198: 93–108
   PubMed Web of Science ®Google Scholar
• Breit T M, Wolvers-Tettero I LM, Beishuizen A, Verhoeven M AJ, Wering E R, Van Dongen J JM. Southern blot patterns, frequencies, and junctional diversity of T-cell receptor 5 gene rearrangements in acute lymphoblastic leukemia. Blood 1993; 82: 3063–70
   PubMed Web of Science ®Google Scholar
• Bonati A, Zanelli P, Savi M, Neri T M. TcR P chain gene rearrangement and expression in human T-cell development and in leukemia. Leukemia 1994; 8: 918–922
   PubMed Web of Science ®Google Scholar
• Kneba M, Bolz I, Linke B, Hiddemann W. Analysis of rearranged T-cell receptor β-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high-resolution PCR fragment analysis. Blood 1995; 86: 3930–7
   PubMed Web of Science ®Google Scholar
• Lefranc M P, Forster A, Rabbitts T H. Rearrangement of two distinct T-cell gamma chain variable region genes in human DNA. Nature 1986; 319: 420–2
   PubMed Web of Science ®Google Scholar
• Lefranc M P, Forster A, Baer M, Stinson M, Rabbitts T H. Diversity and rearrangement of the human T-cell rearranging gamma genes: nine germline variable genes belonging of two subgroups. Cell 1986; 45: 237–24
   PubMed Web of Science ®Google Scholar
• Chen Z, Font M P, Loiseau P, Bories C, Duparc L, Degos L, Lefranc M P, Sigaux F. The Vy locus: cloning of new segments and the study of Vy rearrangements in neoplastic B and T cells. Blood 1988; 72: 776–783
   PubMed Web of Science ®Google Scholar
• Taylor J J, Rowe D, Williamson I K, Christmas S E, Proctor S J, Middleton P G. Detection of T-cell receptor y chain V gene rearrangements using the polymerase chain reaction: application of the study of clonal disease cells in acute lymphoblastic leukemia. Blood 1991; 77: 1989–1995
   PubMed Web of Science ®Google Scholar
• Steward G C, Goulden J N, Potter M N, Oakhill A. The use of polymerase chain reaction to detect minimal residual disease in childhood acute lymphoblastic leukemia. European Journal of Cancer 1993; 29: 1192–8
   Web of Science ®Google Scholar
• Macintyre E A, D'Auriol L, Duparc N, Leverger G, Galibert F, Sigaux F. Use of oligonucleotide probes directed against T-cell antigen receptor gamma delta Variable-(Diversity)-Joining junctional sequences as a general method for detecting minimal residual disease in acute lymphoblastic leukemias. Journal of Clinical Investigation 1990; 86: 2125–2135
   PubMed Web of Science ®Google Scholar
• Trainor K J, Brisco M J, Wan J H, Neoh S, Grist S, Morley A A. Gene rearrangement in B- and T-lymphoproliferative disease detected by polymerase chain reaction. Blood 1991; 78: 192–196
   PubMed Web of Science ®Google Scholar
• Tycko B, Palmer J D, Link M P, Smith S D, Sklar J. Polymerase chain reaction amplification of rearranged antigen receptor genes using junction-specific oligonucleotides: possible application for detection of minimal residual disease in acute lymphoblastic leukemia. Cancer Cell 1989; 7: 47–52
   Google Scholar
• Veeklen H, Tycko B, Sklar J. Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasm by a polymerase chain reaction-mediated ribonuclease protection assay. Blood 1991; 78: 1318–1326
   PubMed Web of Science ®Google Scholar
• Norris M D, Kwan E, Haber M, Marshall C M. Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers. Leukemia 1995; 9: 1779–82
   PubMed Web of Science ®Google Scholar
• Haber M, Kwan E, Zhu L, Marshall G M, Norris M D. Sensitive non-radioactive PCR detection of clonal T-cell receptor-gamma gene rearrangements in childhood acute lymphoblastic leukaemia. British Journal of Haematology 1997; 98: 995–8
   PubMed Web of Science ®Google Scholar
• Biondi A, Champagne F, Rossi V, Giudici G, Cantu-Rajnoldi A, Masera G, Mantovani A, Mak T W, Minden M D. T-cell receptor delta gene rearrangement in T-cell acute lymphoblastic leukemia. Blood 1989; 73: 2133–2138
   PubMed Web of Science ®Google Scholar
• Hata S, Brenner M., Kragel M. Identification of putative human T cell receptor 8 complementary DNA clones. Science 1987; 238: 678–682
   PubMed Web of Science ®Google Scholar
• Takihara Y, Tkachuk D, Michalopoulos E, Champagne E, Reiman J, Minden M, Mak T. Sequence and organization of the diversity, joining and constant region genes of the human T-cell δ chain gene. Proceeding National Academy of Science USA 1988; 85: 6097–6101
   PubMed Web of Science ®Google Scholar
• Satyanarayana K, Hata S, Devlin P, Roncarolo M G, De Vries E, Spits H, Strominger J L, Krangel M S. Genomic organization of the human T-cell receptor α/δ locus. Proceeding National Academy of Science USA 1988; 85: 8166–8170
   PubMed Web of Science ®Google Scholar
• Biondi A, Di Celle P F, Rossi V, Casorati G, Matullo G, Giudici G, Foa R, Migone N. High prevalence of Vδ2-(D)-Dδ3 or Dδ1/2-Dδ3 rearrangements in B-precursor acute lymphoblastic leukemias. Blood 1990; 75: 1834–40
   PubMed Web of Science ®Google Scholar
• Yokota S, Hansen-Hagge T, Bartram C R. T-cell receptor δ gene recombination in common acute lymphoblastic leukemia: preferential use of Vδ2 and frequent involvement of the Jα cluster. Blood 1991; 77: 141–8
   PubMed Web of Science ®Google Scholar
• Van Dongen J JM, Breit T M, Adriaansen H J, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992; 6: 47–59
   PubMed Web of Science ®Google Scholar
• Neale G AM, Menarguez J, Kitchingman G R, Fitzgerald T J, Koehler M, Mirro J, Jr, Goorha R M. Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood 1991; 78: 739–45
   PubMed Web of Science ®Google Scholar
• Cave H, Guidal C, Rohrlich P, Defau M H, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, D'Auriol L, Elion J, Vilmer E, Grandhamp B. Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of Ig H and T-cell receptor genes. Blood 1994; 83: 1892–97
   PubMed Web of Science ®Google Scholar
• Seriu T, Hansen-Hagge T E, Erz D HR, Bartram C M. Improved detection of minimal residual leukemia through modifications of polymerase chain reaction analyses based on clone-specific T-cell receptor junctions. Leukemia 1995; 9: 316–320
   PubMed Web of Science ®Google Scholar
• Taube T, Seeger K, Beyermann B, Hanel C, Duda S, Linderkamp C, Henze G. Multiplex PCR for simultaneous detection of the most frequent T cell receptor-δ gene rearrangements in childhood ALL. Leukemia 1997; 11: 1978–1982
   PubMed Web of Science ®Google Scholar
• Dibenedetto S P, Lo Nigro L, Pine Mayer S, Rovera C, Schiliro G. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 1997; 90: 1226–1232
   PubMed Web of Science ®Google Scholar
• Raimondi S C. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood 1993; 81: 2237–2251
   PubMed Web of Science ®Google Scholar
• Campana D, Pui C H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416–1434
   PubMed Web of Science ®Google Scholar
• Biondi A, Yokota S, Hansen-Hagge T E, Rossi V, Giudici G, Maglia O, Basso G, Tell C, Maserag, Bartram C R. Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 1992; 6: 282–288
   PubMed Web of Science ®Google Scholar
• Kitchingman G R. Immunoglobulin heavy chain gene VH-D junctional diversity at diagnosis in patients with acute lymphoblastic leukemia. Blood 1993; 81: 775–783
   PubMed Web of Science ®Google Scholar
• Steenbergen E J, Verhagen O JHM, Leeuwen E F, Berg H, Borne A EGKr, Schoot C E. Frequent ongoing T-cell receptor rearrangements in childhood B-precursor acute lymphoblastic leukemia: Implications for monitoring minimal residual disease. Blood 1995; 86: 692–706
   PubMed Web of Science ®Google Scholar
• Ghali D W, Panzer S, Fischer S, Tirita A A, Haas O A, Kovar H, Gadner H, Grumayer E RP. Heterogeneity of the T-cell receptor δ gene indicating subclone formation in acute precursor B-cell leukemias. Blood 1995; 85: 2795–2801
   PubMed Web of Science ®Google Scholar
• Beishuizen A, Verhoeven M J, Van Wering E R, Hahlen K, Hooijkaas And Van Dongen J JM. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction. Blood 1994; 83: 2238–2247
   PubMed Web of Science ®Google Scholar
• Saiki R K, Gelfand D M, Stoffel S, Scharf S J, Miguchi R, Horn G T, Mullis K B, Erlich H A. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487–492
   PubMed Web of Science ®Google Scholar
• Baruchel A, Cayuela J M, Macintyre E, Berger R, Sigaux F. Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukemia by single-strand conformation polymorphism studies and highly resolutive PCR-derived methods: implication for a general strategy of minimal residual disease detection. British Journal of Haematology 1995; 90: 85–93
   PubMed Web of Science ®Google Scholar
• Yamada M, Wasserman R, Lange B, Reichard B A, Womer R B, Rovera G. Minimal residual disease in childhood B-lineage lymphocytic leukemia: persistence of leukemic cells during the first 18 months of treatment. New England Journal of Medicine 1990; 323: 448–455
   PubMed Web of Science ®Google Scholar
• Yokota S, Hansen-Hagge T E, Ludwig W D, Reiter A, Raghavackar A, Kleihauer E, Bartram C R. Use of polymerase chain reaction to monitor minimal residual disease in acute lymphocytic leukemia patients. Blood 1991; 77: 331–337
   PubMed Web of Science ®Google Scholar
• Nizet Y, Van Daele S, Lewalle P, Vaerman J L, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux J L, Martial P. Long term follow up of residual disease in ALL patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 1993; 82: 1618–1624
   PubMed Web of Science ®Google Scholar
• Ito Y, Wasserman R, Galili N, Reichard B, Shane S, Lange B, Rovera G. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphocytic leukemia. Journal of Clinical Oncology 1993; 11: 546–553
   PubMed Web of Science ®Google Scholar
• Privitera E, Rivolta A, Ronchetti D, Mosna G, Giudici G, Biondi A. Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. British Journal of Haematology 1996; 92: 653–658
   PubMed Web of Science ®Google Scholar
• Cimino G, Elia L, Rivolta A, Rapanotti M C, Rossi V, Alimena G, Annino I., Canaani E, Lo Coco F, Biondi A. Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive-acute lymphoblastic leukaemia. British Journal of Haematology 1996; 92: 659–664
   PubMed Web of Science ®Google Scholar
• Goulden N, Langlands K, Steward C, Kats F, Potter M, Chessels J, Oakhill A. PCR assessment of bone marrow status in isolated extramedullary relapse of childhood B-precursor acute lymphoblastic leukaemia. British Journal of Haematology 1994; 87: 282–5
   PubMed Web of Science ®Google Scholar
• Kitchingman G. R. Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukaemia. Leukemia 1994; 8: 395–401
   PubMed Web of Science ®Google Scholar
• Ito Y, Miyamura K. Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure?. Leukemia and Lymphoma 1994; 16: 57–64
   PubMed Web of Science ®Google Scholar
• Seriu T., Yokota S., Nakao M, Misawa S., Takaue Y, Koizumi S., Kawai S, Fujimoto T. Prospecting monitoring of minimal residual disease during the course of chemotherapy in patients with lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for auto-transplantation. Leukemia 1995; 9: 615–623
   PubMed Web of Science ®Google Scholar
• Steenbergen E J, Verhagen O J, Van Leeuwen E F, Van Den Berg H, Behrendt H, Slater R M, Van Dem Borne A E, Van Der Schoot C E. Prolonged persistence of PCR-detect-able minimal residual disease after diagnosis of first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. leukemia 1995; 9: 1726–1734
   PubMed Web of Science ®Google Scholar
• Hansen-Hagge T E, Yokota S, Bartram C R. Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T cell receptor y sequences. Blood 1989; 74: 1762–8
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Ludwig W D. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Result and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122–29
   PubMed Web of Science ®Google Scholar
• Schorin M, Blattner S, Gelber R. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85–01. Journal of Clinical Oncology 1994; 12: 740–6
   PubMed Web of Science ®Google Scholar
• Smith M, Arthur D, Camitta B, Carrol A J, Crist W, Caynon P, Gelber R, Heerema N, Korn E L, Link M, Murphy S, Pui C H, Pullen J, Reaman G, Sallan S E, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. Journal of Clinical Oncology 1996; 14: 18–25
   PubMed Web of Science ®Google Scholar
• Uckun F M, Sensel M G, Sun L, Steinherz P G, Trigg M E, Heerema N A, Sather H N, Reaman G H, Gaynon P S. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735–746
   PubMed Web of Science ®Google Scholar
• Iolascon A, Faienza M F, Coppola B, Moretti A, Basso G, Amaru R, Vigano G, Biondi A. Frequent clonal loss of heterozygosity (LOH) in the chromosomal region 1p3.2 occurs in childhood T cell acute lymphoblastic leukemia (T-ALL) carrying rearrangements of the TAL-1 gene. Leukemia 1997; 11: 359–363
   PubMed Web of Science ®Google Scholar
• Van Den Berg, et al. Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia. Medical Pediatric Oncology 1998; 30: 46–51
   PubMedGoogle Scholar
• Moonka D, Loy E Y. A consensus primer to amplify a and P chains of the human T cell receptor. Journal of Immunological Methods 1994; 169: 41–46
   PubMed Web of Science ®Google Scholar
• Roberts M W, Estrov Z, Ouspenskaia M V, Johnston D A, McClain K L, Zipf T F. Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. New England Journal of Medicine 1997; 336: 317–323
   PubMed Web of Science ®Google Scholar
• Dibenedetto S P, Schiliro G. Residual clones in childhood leukemia. New England Journal of Medicine 1997; 337: 50
   PubMedGoogle Scholar
• Greaves M. Silence of leukemic clone. New England Journal of Medicine 1997; 336: 367–9
   PubMed Web of Science ®Google Scholar